Illustrative

FDA says 3-year trial data can support Huntington’s treatment filing

Stock Titan·Jun 17

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

The FDA has stated that data from a 3-year trial can be used to support a filing for a Huntington's treatment. This indicates that a treatment for Huntington's may be moving forward in the regulatory process. The FDA's stance suggests that the trial data may be sufficient for a filing, potentially paving the way for further review.

Full coverage

FDA Action Update, June 2026: Acceptances, Clearances, and Alignments

NeurologyLive·4d ago

Cell therapy weekly: BLA submission planned for Huntington’s gene therapy AMT-130

RegMedNet·Jun 18

The Other Shoe Drops: uniQure Shares Plans To Submit Licensing Application With The FDA for AMT-130

HDBuzz·Jun 17

UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agency

CNBC·Jun 17

HDSA 2026: New oral therapy headed for pivotal Huntington’s trial

huntingtonsdiseasenews.com·Jun 30

UniQure plans Q3 submission for Huntington’s gene therapy after FDA reverses course—again

BioSpace·Jun 17

FDA Reopens Path for UniQure’s AMT-130: 3 Years of Gene Therapy Data Could Support Huntington’s Disease Approval

bio-itworld.com·Jun 18

uniQure: FDA's Latest Stance On Huntington's BLA Sends Stock Soaring (NASDAQ:QURE)

Seeking Alpha·Jun 17

View original report at Stock Titan ↗

Fetching the latest headlines…